These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 1730087)

  • 1. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
    Li XK; Lijnen HR; Nelles L; Van Hoef B; Stassen JM; Collen D
    Blood; 1992 Jan; 79(2):417-29. PubMed ID: 1730087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
    Collen D; Lijnen HR; Bulens F; Vandamme AM; Tulinsky A; Nelles L
    J Biol Chem; 1990 Jul; 265(21):12184-91. PubMed ID: 2115513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
    Lijnen HR; Li XK; Nelles L; Hu MH; Collen D
    Eur J Biochem; 1992 Apr; 205(2):701-9. PubMed ID: 1533368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator.
    Nelles L; Li XK; Vanlinthout I; De Cock F; Lijnen HR; Collen D
    Thromb Haemost; 1992 Apr; 67(4):445-52. PubMed ID: 1631793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
    Li XK; Lijnen HR; Nelles L; Hu MH; Collen D
    Biochim Biophys Acta; 1992 Sep; 1159(1):37-43. PubMed ID: 1390910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
    Lijnen HR; Webb PD; Van Hoef B; De Cock F; Stassen JM; Prior SD; Collen D
    Thromb Haemost; 1992 Feb; 67(2):239-47. PubMed ID: 1621244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    J Biol Chem; 1990 Apr; 265(10):5677-83. PubMed ID: 2156824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.
    Vaughan DE; Declerck PJ; Van Houtte E; De Mol M; Collen D
    Thromb Haemost; 1992 Jul; 68(1):60-3. PubMed ID: 1514173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
    Holvoet P; Dewerchin M; Stassen JM; Lijnen HR; Tollenaere T; Gaffney PJ; Collen D
    Circulation; 1993 Mar; 87(3):1007-16. PubMed ID: 8443877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.
    Holvoet P; Laroche Y; Stassen JM; Lijnen HR; Van Hoef B; De Cock F; Van Houtven A; Gansemans Y; Matthyssens G; Collen D
    Blood; 1993 Feb; 81(3):696-703. PubMed ID: 8427962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of residues K296-G302 from the slowly-cleared tissue-type plasminogen activator t-PA del (G) leads to partial loss of plasminogen activating activity.
    Dodd I; Browne MJ; Chapman CG; Cronk D; Hastwell C; Wilson S; Robinson JH
    Biologicals; 1993 Sep; 21(3):269-74. PubMed ID: 8117440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
    Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D
    Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
    Lu HR; Lijnen HR; Stassen JM; Collen D
    Blood; 1991 Jul; 78(1):125-31. PubMed ID: 1906351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
    Collen D; Lijnen HR; Vanlinthout I; Kieckens L; Nelles L; Stassen JM
    Thromb Haemost; 1991 Feb; 65(2):174-80. PubMed ID: 1905070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
    Declerck PJ; Lijnen HR; Verstreken M; Moreau H; Collen D
    Blood; 1990 May; 75(9):1794-800. PubMed ID: 1691934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
    Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
    Nelles L; Lijnen HR; Collen D; Holmes WE
    J Biol Chem; 1987 Aug; 262(22):10855-62. PubMed ID: 2956260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.